Novo Nordisk AS (MEX:NOVOB) Purchase Of Investment : MXN-54,631 Mil (TTM As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Novo Nordisk AS Purchase Of Investment?

Novo Nordisk AS's purchase of investment for the three months ended in Dec. 2024 was MXN-1,034 Mil. It means Novo Nordisk AS spent MXN1,034 Mil on purchasing investments. Novo Nordisk AS's purchase of investment for the trailing twelve months (TTM) ended in Dec. 2024 was MXN-54,631 Mil.

Compared with last quarter (MXN-24,726 Mil in Sep. 2024 ), Novo Nordisk AS spent less money on purchasing investments in Dec. 2024 (MXN-1,034 Mil).

Novo Nordisk AS Purchase Of Investment Historical Data

The historical data trend for Novo Nordisk AS's Purchase Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk AS Purchase Of Investment Chart

Novo Nordisk AS Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Purchase Of Investment

Get a 7-Day Free Trial

-22,172.33

-27,024.96

-33,003.28

-58,021.49

Novo Nordisk AS Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Purchase Of Investment	Get a 7-Day Free Trial															-2,354.36	-2,806.45	-26,065.51	-24,725.72	-1,033.69

Novo Nordisk AS Purchase Of Investment Calculation

Purchase of Investments represents cash outflow on the purchase of investments in securities.

Purchase Of Investment for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-54,631 Mil.

Novo Nordisk AS Purchase Of Investment Related Terms

Thank you for viewing the detailed overview of Novo Nordisk AS's Purchase Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.

Novo Nordisk AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novo Nordisk AS (MEX:NOVOB) » Definitions » Purchase Of Investment

Comparable Companies

Traded in Other Exchanges

NONOF:USA NVO:USA NVO:Mexico 0TDD:UK NOVOBc:UK 0QIU:UK NOVO B:Denmark NOV:Germany NOV:Germany NOVA:Germany NOV:Germany NOV:Germany NOVA:Germany NVON:Canada N1VO34:Brazil NOV:Bulgaria NNO2:Austria

Address

Novo Alle 1, Bagsvaerd, DNK, 2880

Website

https://www.novonordisk.com

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Novo Nordisk AS Headlines

No Headlines